HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use HEPARIN SODIUM IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for HEPARIN SODIUM IN SODIUM CHLORIDE INJECTION. HEPARIN SODIUM IN SODIUM CHLORIDE INJECTION, for intravenous use Initial U.S. Approval: 1939 RECENT MAJOR CHANGESINDICATIONS AND USAGEHEPARIN SODIUM IN SODIUM CHLORIDE INJECTION at a concentration of 2 units/mL is indicated as an anticoagulant to maintain catheter patency. (1) DOSAGE AND ADMINISTRATIONInfuse through intravenous catheter at a rate of 6 units per hour. (2.2) DOSAGE FORMS AND STRENGTHSCONTRAINDICATIONSHeparin Sodium in Sodium Chloride Injection is contraindicated in patients with the following conditions: (4)
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONSMost common adverse reactions are: hemorrhage, thrombocytopenia, HIT and HITT, hypersensitivity, and elevations of aminotransferase levels. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONSDrugs that interfere with platelet aggregation or drugs that counteract coagulation may induce bleeding. (7) USE IN SPECIFIC POPULATIONSGeriatric Use: A higher incidence of bleeding has been reported in patients over 60 years of age, especially women (5.6, 8.5) See 17 for PATIENT COUNSELING INFORMATION. Revised: 9/2019 |

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
heparin sodium in 0.9% sodium chloride injection Highlights
To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at(800) 438-1985.
(800)-332-1088.